Home
KG Jebsen Center for Genome-Directed Cancertherapy
Scientific aims

Our vision

It is now possible to study the molecular mechanisms that cause cancer spread, as well as treatment resistance, and this provides opportunities for more personalized cancer therapy.

Mohn Lab
Photo:
UiB

Main content

Although we have seen major advances in cancer treatment in recent years, it is still the case that most patients with widespread dissemination of cancer disease cannot be cured. In recent years, however, major advances have been made in the laboratory technology for genetic analysis. This now makes it possible to study the molecular mechanisms that cause cancer spread, as well as treatment resistance. Such analyzes will fundamentally change the way we diagnose and treat cancer patients, and give us the opportunity for far more personalized therapy.

At K.G. Jebsen we will carry out new clinical trials in several different cancers to explore how changes in the cancer genome affect the sensitivity to treatment and how cancer therapy should be designed to exploit the gene errors that regulate the cancer cells. In particular, we will concentrate on breast cancer, colon cancer, sarcoma, lung cancer and bladder cancer and prostate. The hope is not only to find better methods to identify which patients benefit from specific therapies, but also to develop more effective therapies that can lead to the healing of many patients we cannot cure today.